Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00260429 · ClinicalTrials.gov registry record · Phase 3

Collagenase in the Treatment of Dupuytrens Disease

A Phase 3 study of Dupuytren's Disease, sponsored by Stony Brook University.

Completed
Registry status
Phase 3
Development phase
38
Enrollment target
1
Study location

NCT00260429 is a Phase 3 study of Dupuytren's Disease that has completed, run by Stony Brook University. The registered enrollment target is 38 participants, below the 53-participant average among 4 other Dupuytren's Disease trials with a reported enrollment target (28% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00260429, a Phase 3 study of Dupuytren's Disease, has completed, sponsored by Stony Brook University.

COMPLETED
Registry status
Phase 3
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to determine if collagenase will reduce the degree of contracture in the primary joint in subjects with Dupuytren's disease. This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 and AUX-CC-859) and 7 non-pivotal studies were evaluated.

Conditions Studied

Interventions

  • BIOLOGICAL collagenase clostridium histolyticum

Study Locations (1)

New York

  • Stony Brook University Hospital and Mediacl Center - Stony Brook

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2003-06
Est. Completion 2008-04
Phase Phase 3

Sponsor

Stony Brook University

127 total trials

What the Registry Record Tells You About NCT00260429

The ClinicalTrials.gov registry entry for NCT00260429 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 53-participant average among 4 other Dupuytren's Disease trials with a reported enrollment target (28% lower). The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dupuytren's Disease appearing as the primary indexed condition, and to 1 intervention - of which collagenase clostridium histolyticum is the first listed.

NCT00260429 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00260429 about?

NCT00260429 is a clinical study titled "Collagenase in the Treatment of Dupuytrens Disease". The purpose of the study is to determine if collagenase will reduce the degree of contracture in the primary joint in subjects with Dupuytren's disease. This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the...

What is the current status of trial NCT00260429?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 38 participants. The study started on 2003-06. Estimated completion is 2008-04.

What conditions does trial NCT00260429 study?

This clinical trial studies the following conditions: Dupuytren's Disease.

What interventions are being tested in trial NCT00260429?

The interventions under investigation include: collagenase clostridium histolyticum (BIOLOGICAL).

Who is sponsoring clinical trial NCT00260429?

This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00260429 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dupuytren's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.